Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients

Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Shuntaro, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954173/
https://www.ncbi.nlm.nih.gov/pubmed/31866617
http://dx.doi.org/10.3960/jslrt.19028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954173/
https://www.ncbi.nlm.nih.gov/pubmed/31866617
http://dx.doi.org/10.3960/jslrt.19028

Ejemplares similares